MELK: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: MELK

NCBI ID: G9833

MELK

MELK: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

MELK (Maternal embryonic leucine zipper kinase (isoform 3)) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MELK is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and testes. It is involved in the regulation of cellular processes that are important for the development, growth, and maintenance of tissues.

One of the things that makes MELK an interesting potential drug target is its role in the development and progression of cancer. MELK has been shown to be involved in the regulation of cell division, which is a critical process for the growth and development of cancer cells. In addition, MELK has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to support the growth and expansion of cancer cells.

Another potential drug target for MELK is its role in the regulation of neurodegenerative diseases. MELK has been shown to be involved in the regulation of the aggregation of beta-amyloid plaques, which are a hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's. In addition, MELK has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of the nervous system.

MELK has also been shown to be involved in the regulation of autoimmune disorders. In autoimmune disorders, the immune system attacks the body's own tissues and can cause a range of symptoms, including inflammation, pain, and fatigue. MELK has been shown to be involved in the regulation of the immune response, which is important for the function of the immune system.

In addition to its potential drug target properties, MELK is also a potential biomarker for a variety of diseases. For example, MELK has been shown to be a potential biomarker for pancreatic cancer, as high levels of MELK have been associated with poor prognosis in pancreatic cancer patients. In addition, MELK has also been shown to be a potential biomarker for neurodegenerative diseases, as levels of MELK have been shown to be elevated in the brains of individuals with neurodegenerative diseases.

Overall, MELK is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in the regulation of cellular processes and its potential as a drug or biomarker.

Protein Name: Maternal Embryonic Leucine Zipper Kinase

Functions: Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis

The "MELK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MELK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets